Exact Sciences Corporation (NASDAQ: EXAS) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Exact Sciences Corporation to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation.
This table compares Exact Sciences Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Exact Sciences Corporation||-83.08%||-36.36%||-32.85%|
|Exact Sciences Corporation Competitors||-3,989.23%||-119.42%||-44.20%|
85.2% of Exact Sciences Corporation shares are held by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.0% of Exact Sciences Corporation shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings for Exact Sciences Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Exact Sciences Corporation||0||3||10||0||2.77|
|Exact Sciences Corporation Competitors||469||2235||6132||118||2.66|
Exact Sciences Corporation presently has a consensus price target of $43.54, suggesting a potential downside of 9.43%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.12%. Given Exact Sciences Corporation’s competitors higher possible upside, analysts plainly believe Exact Sciences Corporation has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Exact Sciences Corporation and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Exact Sciences Corporation||$169.37 million||-$129.74 million||-37.26|
|Exact Sciences Corporation Competitors||$207.83 million||-$2.34 million||0.17|
Exact Sciences Corporation’s competitors have higher revenue and earnings than Exact Sciences Corporation. Exact Sciences Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Exact Sciences Corporation has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Exact Sciences Corporation’s competitors have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
What are top analysts saying about Exact Sciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exact Sciences Corporation and related companies.